Shopping Cart
- Remove All
- Your shopping cart is currently empty
EZH2-IN-9 is a potent inhibitor of EZH2, which, through overexpression or mutations in the SET region (Y641F, Y641N, A687V, A677G point mutations), causes abnormal elevations in H3K27me3 and contributes to the growth and development of various tumours (e.g., breast cancer, prostate cancer, leukaemia). EZH2-IN-9 has shown potential for cancer research.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $2,140 | 6-8 weeks | |
50 mg | $2,785 | 6-8 weeks | |
100 mg | $3,520 | 6-8 weeks |
Description | EZH2-IN-9 is a potent inhibitor of EZH2, which, through overexpression or mutations in the SET region (Y641F, Y641N, A687V, A677G point mutations), causes abnormal elevations in H3K27me3 and contributes to the growth and development of various tumours (e.g., breast cancer, prostate cancer, leukaemia). EZH2-IN-9 has shown potential for cancer research. |
Molecular Weight | 596.09 |
Formula | C28H32ClF2N3O5S |
Cas No. | 2700897-24-9 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.